MEF2C and acute myeloid leukemia: Using over 750 pretreatment bone marrow specimens from pediatric patients enrolled in a recent cooperative group phase 3 trial, ours is the first study to quantify MEF2C mRNA abundance by RT-PCR and comprehensively examine the relationship between MEF2C expression and disease characteristics as well as treatment outcome in pediatric AML.